Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT).

Levy ML, Dekhuijzen PN, Barnes PJ, Broeders M, Corrigan CJ, Chawes BL, Corbetta L, Dubus JC, Hausen T, Lavorini F, Roche N, Sanchis J, Usmani OS, Viejo J, Vincken W, Voshaar T, Crompton GK, Pedersen S.

NPJ Prim Care Respir Med. 2016 Apr 21;26:16017. doi: 10.1038/npjpcrm.2016.17. Review.

2.

Retail sales of inhalation devices in European countries: so much for a global policy.

Lavorini F, Corrigan CJ, Barnes PJ, Dekhuijzen PR, Levy ML, Pedersen S, Roche N, Vincken W, Crompton GK; Aerosol Drug Management Improvement Team.

Respir Med. 2011 Jul;105(7):1099-103. doi: 10.1016/j.rmed.2011.03.012. Epub 2011 Apr 13.

3.

Hyperventilation in men claiming compensation for benign asbestos-related diseases.

Crompton GK.

J R Coll Physicians Edinb. 2010 Dec;40(4):297-300. doi: 10.4997/JRCPE.2010.402.

PMID:
21132133
4.

The article by Daley-Yates et al.

Crompton GK.

Clin Ther. 2010 May;32(5):996-7; author reply 997-1000. doi: 10.1016/j.clinthera.2010.05.006. No abstract available.

PMID:
20685508
5.

The ADMIT series--issues in inhalation therapy. 5) Inhaler selection in children with asthma.

Pedersen S, Dubus JC, Crompton GK; ADMIT Working Group.

Prim Care Respir J. 2010 Sep;19(3):209-16. doi: 10.4104/pcrj.2010.00043. Review.

6.

Inhaler choice and inhalation technique: key factors for asthma control.

Lavorini F, Levy ML, Dekhuijzen PN, Crompton GK; ADMIT Working Group.

Prim Care Respir J. 2009 Dec;18(4):241-2. doi: 10.4104/pcrj.2009.00069. No abstract available.

7.

The ADMIT series--issues in inhalation therapy. 3) Mild persistent asthma: the case for inhaled corticosteroid therapy.

Corrigan CJ, Levy ML, Dekhuijzen PR, Crompton GK; ADMIT Working Group.

Prim Care Respir J. 2009 Sep;18(3):148-58. doi: 10.4104/pcrj.2009.00035. Review.

8.

The ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness.

Broeders ME, Sanchis J, Levy ML, Crompton GK, Dekhuijzen PN; ADMIT Working Group.

Prim Care Respir J. 2009 Jun;18(2):76-82. doi: 10.4104/pcrj.2009.00025. Review.

9.

Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD.

Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK.

Respir Med. 2008 Apr;102(4):593-604. Epub 2007 Dec 20. Review.

10.

Issues in inhalation therapy: a new series of papers from the ADMIT Working Group.

Dekhuijzen PN, Crompton GK.

Prim Care Respir J. 2007 Dec;16(6):335-6. No abstract available.

11.

Importance of inhaler devices in the management of airway disease.

Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, Barnes PJ.

Respir Med. 2008 Jan;102(1):10-9. Epub 2007 Oct 17. Review.

12.

Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma.

Bradshaw TA, Matusiewicz SP, Crompton GK, Innes JA, Greening AP.

Respir Med. 2008 Jan;102(1):143-9. Epub 2007 Sep 14.

13.

Inhaler technique blind spot.

Crompton GK.

Eur Respir J. 2006 May;27(5):1070-1; author reply 1071. No abstract available.

14.

Aerosol delivery devices.

Crompton GK, Barnes PJ.

Chest. 2006 May;129(5):1388-9; author reply 1389. No abstract available.

PMID:
16685035
15.

The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team.

Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, Dekhuijzen R, Dubus JC, Magnan A, Massone F, Sanchis J, Viejo JL, Voshaar T; Aerosol Drug Management Improvement Team.

Respir Med. 2006 Sep;100(9):1479-94. Epub 2006 Feb 21. Review.

16.

How to achieve good compliance with inhaled asthma therapy.

Crompton GK.

Respir Med. 2004 Oct;98 Suppl B:S35-40. Review.

17.

Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think?

Hartung TK, Allbutt H, Dewar M, Innes JA, Crompton GK.

Respiration. 2002;69(4):314-9.

PMID:
12169743
18.

Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study.

Bergquist P, Crompton GK.

Eur Respir J. 2001 Jul;18(1):248. No abstract available.

19.

The ISOLDE trial. Pharmaceutical companies should admit high cost of treatment.

Crompton GK.

BMJ. 2000 Nov 25;321(7272):1349-50. No abstract available.

PMID:
11186444
20.

Fluticasone propionate bioavailability in asthma.

Crompton GK.

Lancet. 2000 Nov 11;356(9242):1681-2; author reply 1682. No abstract available.

PMID:
11089842
21.
22.
23.

Comparison of Pulmicort pMDI plus Nebuhaler and Pulmicort Turbuhaler in asthmatic patients with dysphonia.

Crompton GK, Sanderson R, Dewar MH, Matusiewicz SP, Ning AC, Jamieson AH, McLean A, Greening AP.

Respir Med. 2000 May;94(5):448-53.

24.

Pet ownership and asthma morbidity.

Simpson AJ, Matusiewicz SP, Greening AP, Crompton GK.

Respir Med. 2000 Jan;94(1):91-2. No abstract available.

25.

Hypersensitivity pneumonitis associated with co-proxamol (paracetamol + dextropropoxyphene) therapy.

Matusiewicz SP, Wallace WA, Crompton GK.

Postgrad Med J. 1999 Aug;75(886):475-6.

26.

Emergency pre-hospital management of patients admitted with acute asthma.

Simpson AJ, Matusiewicz SP, Brown PH, McCall IA, Innes JA, Greening AP, Crompton GK.

Thorax. 2000 Feb;55(2):97-101.

27.

Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease.

Dewar MH, Jamieson A, McLean A, Crompton GK.

Respir Med. 1999 May;93(5):342-4.

28.

Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids.

Crompton GK, Ayres JG, Basran G, Schiraldi G, Brusasco V, Eivindson A, Jamieson AH, Olsson H.

Am J Respir Crit Care Med. 1999 Mar;159(3):824-8.

PMID:
10051257
29.

Starting home nebulizer therapy: patients' expectations and subsequent outcome at 2 months.

Simpson AJ, Tweeddale PM, Crompton GK.

Respir Med. 1998 Aug;92(8):1000-2.

30.

Making the diagnosis of asthma. Trial of steroids is useful.

Crompton GK.

BMJ. 1998 Jan 10;316(7125):150. No abstract available.

31.

Comparative efficacy and potency of ipratropium via Turbuhaler and pressurized metered-dose inhaler in reversible airflow obstruction.

Böllert FG, Matusiewicz SP, Dewar MH, Brown GM, McLean A, Greening AP, Crompton GK.

Eur Respir J. 1997 Aug;10(8):1824-8.

32.

The Spacehaler for delivery of salbutamol: a comparison with the standard metered-dose inhaler plus Volumatic spacer device.

Gunawardena KA, Sohal T, Jones JI, Upchurch FC, Crompton GK.

Respir Med. 1997 May;91(5):311-6.

33.

Effectiveness of four different inhalers in COPD.

Crompton GK.

Thorax. 1996 Apr;51(4):454. No abstract available.

34.

Glucocorticoid resistance in asthma.

Barnes PJ, Greening AP, Crompton GK.

Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 2):S125-40. Review. No abstract available.

PMID:
7489120
35.

Peak inspiratory flow through Turbuhaler in acute asthma.

Brown PH, Ning AC, Greening AP, McLean A, Crompton GK.

Eur Respir J. 1995 Nov;8(11):1940-1.

36.

Electronic diaries for asthma.

Tiplady B, Crompton GK, Brackenridge D.

BMJ. 1995 Jun 3;310(6992):1469. No abstract available.

37.

Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations.

Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK.

Eur Respir J. 1995 Apr;8(4):590-2.

38.

Non-tuberculous pulmonary infections in Scotland: a cluster in Lothian?

Böllert FG, Watt B, Greening AP, Crompton GK.

Thorax. 1995 Feb;50(2):188-90.

39.

Effectiveness of nebulised salbutamol administered in ambulances to patients with severe acute asthma.

Fergusson RJ, Stewart CM, Wathen CG, Moffat R, Crompton GK.

Thorax. 1995 Jan;50(1):81-2.

40.

Medical personnel's knowledge of the ability to use inhaling devices.

Crompton GK.

Chest. 1995 Jan;107(1):290. No abstract available.

PMID:
7880268
41.

Matching inhalers and spacer devices.

Crompton GK, Prowse K.

BMJ. 1994 Dec 10;309(6968):1584. No abstract available.

42.

Pneumocystis carinii in bronchoalveolar lavage fluid and bronchial washings.

Matusiewicz SP, Fergusson RJ, Greening AP, Crompton GK, Burns SM.

BMJ. 1994 May 7;308(6938):1206-7. No abstract available.

43.

Pulmonary Mycobacterium malmoense and aspergillus infection: a fatal combination?

Böllert FG, Sime PJ, MacNee W, Crompton GK.

Thorax. 1994 May;49(5):521-2.

44.

Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis?

Matusiewicz SP, Williamson IJ, Sime PJ, Brown PH, Wenham PR, Crompton GK, Greening AP.

Eur Respir J. 1993 Oct;6(9):1282-6.

PMID:
8287944
45.

Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects.

Brown PH, Matusiewicz SP, Shearing C, Tibi L, Greening AP, Crompton GK.

Thorax. 1993 Oct;48(10):967-73.

46.

Bronchodilator treatment in asthma. Regular treatment with beta agonists remains unevaluated.

Crompton GK.

BMJ. 1993 Jun 12;306(6892):1610; author reply 1611. No abstract available.

48.

High dose inhaled steroid therapy and the cortisol stress response to acute severe asthma.

Brown PH, Blundell G, Greening AP, Crompton GK.

Respir Med. 1992 Nov;86(6):495-7.

PMID:
1470707
49.

Pulmonary eosinophilia with systemic features: therapy and prognosis.

Capewell S, Chapman BJ, Alexander F, Greening AP, Crompton GK.

Respir Med. 1992 Nov;86(6):485-90.

PMID:
1470705
50.

Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists.

Brown PH, Lenney J, Armstrong S, Ning AC, Crompton GK.

Eur Respir J. 1992 Oct;5(9):1143-5.

PMID:
1358674

Supplemental Content

Loading ...
Support Center